



AMENDED CLAIMS 6, 9 AND 29 (CLEAN COPY)

D1 6. (Amended Twice) A pharmaceutical composition comprising
5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiazolidine-
2,4-dione or a pharmaceutically acceptable salt thereof,
and pharmaceutically acceptable excipients with low water content comprising anhydrous
lactose, microcrystalline cellulose, magnesium stearate, and talc.

D2 9. (Amended Three Times) The pharmaceutical composition according to claim 6
wherein the pharmaceutically acceptable excipients are
between 100 and 400,000 parts by weight of anhydrous lactose,
between 1000 and 10,000 parts by weight of microcrystalline cellulose, and
between 10 and 500 parts by weight of magnesium stearate,
expressed in parts by weight per 100 parts of 5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-
quinazolinyl]methoxy]phenyl-methyl]thiazolidine-2,4-dione, or of one of its phar-
maceutically acceptable salts.

D3 29. (Amended Once) The pharmaceutical composition according to claim 6 consisting
of

5-[[4-[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl] thiazolidine-
2,4-dione or a pharmaceutically acceptable salt thereof 9%

Microcrystalline cellulose	20%
Anhydrous lactose	66%
Magnesium Stearate	0.5%
Talc	4.5%



AMENDED CLAIMS 6, 9 AND 29 (MARKED UP VERSION)

6. A pharmaceutical composition comprising

5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiadiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof,

and pharmaceutically acceptable excipients with low water content and an antioxidant

comprising anhydrous lactose, microcrystalline cellulose, magnesium stearate, and talc.

9. The pharmaceutical composition according to claim 6 or 7 wherein the pharmaceutically acceptable excipients are selected among from the following:

between 100 and 400,000 parts by weight of anhydrous lactose,

~~between 50 and 500 parts by weight of pregelatinized starch,~~

between 1000 and 10,000 parts by weight of microcrystalline cellulose,

~~between 10 and 500 parts by weight of erospovidone,~~

~~between 10 and 500 parts by weight of silicon dioxide,~~

~~between 10 and 500 parts by weight of hydrogenated vegetable oil,~~

between 10 and 500 parts by weight of magnesium stearate,

~~between 10 and 500 parts by weight of hydroxypropyl methylcellulose,~~

~~between 10 and 500 parts by weight of hydroxypropyl cellulose,~~

~~between 1000 and 10,000 parts by weight of Mannitol,~~

~~between 10 and 500 parts by weight of stearic acid,~~

~~between 10 and 500 parts by weight of Titanium Dioxide,~~

expressed in parts by weight per 100 parts of 5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiadiazolidine-2,4-dione, or of one of its pharmaceutically acceptable salts.

29. (Amended Once) The pharmaceutical composition according to claim 6 consisting of

5-[[4-[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiadiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof	9%
Microcrystalline cellulose	20%
Anhydrous lactose	66%
Magnesium Stearate	0.5%

Talc



4.5%

RECEIVED
—DEC 04 2002
TECH CENTER 1600/2900